340B Advocacy Alliance Bulletin
The Health Resources and Services Administration today sent a final warning letter to Johnson & Johnson urging the company to inform the agency by Monday, Sept. 30 that it would halt its proposed 340B rebate model scheduled to go into effect next month.
The deadline has been extended for representatives to sign onto a letter that urges the Department of Health and Human Services to take action to stop Johnson & Johnson鈥檚 plan 鈥渢o upend more than 30 years of federal law by delaying access to 340B Drug Pricing Program (340B) discounts on鈥
Urge your representatives to sign letter to HHS asking it to take action to protect providers from 鈥榙evastating鈥 J&J 340B proposal; deadline is Sept. 20.
The Health Resources and Services Administration today told Johnson & Johnson that the company鈥檚 publicly announced plans to implement a 340B rebate model 鈥渧iolates J&J鈥檚 obligations under the 340B statute, and HRSA expects J&J to cease implementation of it.鈥
The AHA, 340B Health and the American Society of Health-System Pharmacists last week filed an amicus brief in a federal district court in Missouri, defending the state's law protecting 340B pricing for contract pharmacy arrangements.
If Johnson & Johnson moves forward with its plan to undermine the 340B Drug Pricing Program by unilaterally imposing a rebate model rather than the longstanding upfront discount model, the Health Resources and Services Administration should take 鈥渋mmediate enforcement action,鈥 including鈥
J&J announces major change to 340B pricing; HRSA responds to preemptive AHA advocacy.
The Health Resources and Services Administration Aug. 7 requested public comment on how petitioners file initial claims in the 340B Administrative Dispute Resolution process and how it affects stakeholders鈥 administrative load.
As the annual 340B hospital recertification period approaches, the Health Resources and Services Administration鈥檚 Office of Pharmacy Affairs is hosting a certification webinar on Wednesday, Aug. 7 from 1-2 p.m. ET.
AHA, others file briefs in Maryland, West Virginia to prevent injunctions against 340B pricing for contract pharmacy arrangements